Denosumab, Amgen's drug candidate for osteoporosis, significantly decreased the risk of hip and spine fractures in a three-year study of 7,800 postmenopausal women with the disease. The trial data will allow Amgen to file for FDA approval of the treatment, which is expected to compete with other bone drugs, including Merck & Co.'s Fosamax and Novartis' Reclast.

Related Summaries